Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitzgibbon, J.
Right arrow Articles by Young, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitzgibbon, J.
Right arrow Articles by Young, B. D.
[Cancer Research 65, 9152-9154, October 15, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Association between Acquired Uniparental Disomy and Homozygous Gene Mutation in Acute Myeloid Leukemias

Jude Fitzgibbon, Lan-Lan Smith, Manoj Raghavan, Matthew L. Smith, Silvana Debernardi, Spyros Skoulakis, Debra Lillington, T. Andrew Lister and Bryan D. Young

Cancer Research UK Medical Oncology Laboratory, Barts and the Royal London School of Medicine, Queen Mary College, London, United Kingdom

Requests for reprints: Bryan D. Young, Cancer Research UK Medical Oncology Laboratory, Barts and the Royal London School, Charterhouse Square, United Kingdom. Phone: 44-207-882-6002; Fax: 44-207-882-6002; E-mail: bryan.young{at}cancer.org.uk.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
Genome-wide single nucleotide polymorphism analysis has revealed large-scale cryptic regions of acquired homozygosity in the form of segmental uniparental disomy in ~20% of acute myeloid leukemias. We have investigated whether such regions, which are the consequence of mitotic recombination, contain homozygous mutations in genes known to be mutational targets in leukemia. In 7 of 13 cases with uniparental disomy, we identified concurrent homozygous mutations at four distinct loci (WT1, FLT3, CEBPA, and RUNX1). This implies that mutation precedes mitotic recombination which acts as a "second hit" responsible for removal of the remaining wild-type allele, as has recently been shown for the JAK2 gene in myeloproliferative disorders.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Recently, a novel form of abnormality in acute myeloid leukemia (AML), uniparental disomy, has been revealed through the application of single nucleotide polymorphism (SNP) genotype array technology (1). Uniparental disomy, which cannot be detected by conventional cytogenetic methods, was observed in ~20% of the AMLs studied. The affected regions are evident as large stretches of somatically acquired homozygosity, usually continuing from a certain point on the chromosome to the telomere and have the hallmarks of mitotic recombination, because there is no net change in copy number in the affected region. A consequence of a mitotic recombination event is the generation of two daughter cells, each with the reciprocal chromosomal products. The homozygosity observed in AML is due to the outgrowth of one of these daughter cells. Because this phenomenon has only recently been described, the nature of the selective advantage to the cell, gained by uniparental disomy, has been uncertain. However, it was noted, first, that the distribution of affected chromosomal regions seemed nonrandom, and second, that some of the regions of uniparental disomy included genes known to be mutated in a proportion of AML. The potential relationship between acquired uniparental disomy and gene mutation was therefore investigated.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
10K GeneChip assay. DNA was extracted using standard phenol-chloroform techniques or from the organic phase of TRIzol (Invitrogen, Carlsbad, CA). DNA probes were prepared using the GeneChip mapping assay protocol (Affymetrix, Inc., Santa Clara, CA) with the modification that PCR products were purified using the Ultrafree-MC filtration column (Millipore Corp., Billerica, MA). Signal intensity data was analyzed by the GeneChip DNA analysis software, which uses a model algorithm to generate SNP calls.

Mutation analysis. Bone marrow samples were collected and analyzed in accordance with the requirements of the Local Research Ethics Committee. Cases were classified according to the French-American-British system and subsequently according to WHO. DNA was extracted using standard phenol-chloroform methodologies. Primers and precise amplification conditions were derived either from previously published studies or cDNA/genomic comparison and are available on request. Mutation screening was done for the entire coding region (CCND3, CDKN2A, CDKN2B, PU.1, and CEBPA) or specific exons [WT1 (7-10), FLT3 (exons 14-15 and 20), RUNX1 (exons 3-5), and MLL (PTD)]. PCR products were sequenced directly or cloned by TOPO TA cloning (Invitrogen Ltd., Paisley, United Kingdom), plasmid DNA extracted and sequenced by use of an ABI 377 DNA sequencer (PE Applied Biosystems, Foster City, CA). For direct sequencing, unincorporated primer was removed by ultrafiltration using a Centricon YM-100,000 filter device (Millipore). Sequencing data were analyzed using DNASTAR, Inc. (Madison, WI).


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
SNP genotype arrays were used to analyze DNA samples from a series of AMLs. As described previously (1), such an analysis can detect the presence of acquired homozygosity and by evaluation of the signal values can determine whether it is due to mitotic recombination or deletion. To investigate this phenomenon further, we selected a total of 13 primary AMLs with uniparental disomy encompassing regions known to harbor genes potentially mutated in AML (Table 1). These included previously described and new cases of uniparental disomy which were confirmed by analysis of the SNP signal values and the karyotype.


View this table:
[in this window]
[in a new window]
  		Table 1. Thirteen examples of uniparental disomy were investigated for mutation

 
Sequence analysis was done on nine genes in the appropriate leukemias (Table 1). Mutations were detected at four distinct loci (WT1, FLT3, CEBPA, and RUNX1) in 7 of the 13 leukemias examined. In all cases, sequence analysis indicated a homozygous mutation with no evidence of the wild-type sequence. In Fig. 1, the sequence traces showing a homozygous insertional mutation of the WT1 gene are illustrated along with the homozygosity map for chromosome 11. Similarly, a homozygous single-base insertion of the RUNX1 gene is shown with the concurrent homozygosity of 21q (Fig. 1). It was notable that uniparental disomy of 13q was associated with homozygous internal tandem duplication mutation of FLT3 (FLT3-ITD) in four separate cases.



View larger version (38K):
[in this window]
[in a new window]
  		Figure 1. Display of uniparental disomy on 11p and 21q in two AML samples. Heterozygous calls (red) and homozygous calls (blue). The corresponding sequencing traces showing 1584ins16bp WT1 and 970insA RUNX1 homozygous mutations. WT and RUNX1 duplicated segments (underlined in orange).

 
The presence of a mutation and the absence of the wild-type sequence has previously been reported in AML: WT1 (3), CEBPA (4), and RUNX1 (5, 6). Such a situation could arise by several mechanisms, including the deletion of wild-type allele to yield a hemizygous state, amplification of the mutant allele, or mitotic recombination. Without accurate copy number information, it has been difficult to distinguish between these possibilities. The high degree of association between uniparental disomy and homozygous mutation presented here suggests that uniparental disomy may account for a substantial proportion of cases exhibiting a lack of the wild-type allele. Indeed, it has been previously suggested that homozygous RUNX1 mutations in leukemias could be due to mitotic recombination (5). Because relatively large regions of the genome are involved, there may be more than one potential mutational target in a given region of uniparental disomy. One example of WT1 mutation was observed in the three examples of UPD11p suggesting other potential targets in this region. Similarly, because no mutations were detected in the CCND3, CDKN2A, CDKN2B, and MLL genes, our data would suggest that there may be other targets in UPD6p, UPD9p, and UPD11q, respectively.

FLT3-ITD mutation in the heterozygous state is a recognized poor prognostic risk factor for AML. Additionally, the loss of the wild-type FLT3 allele in leukemias with a FLT3 mutation in ~10% of patients with normal karyotype AML is associated with a worse outcome (7). Hence, the association between loss of the wild-type FLT3 allele and UPD13q could suggest that the presence of uniparental disomy may be linked to clinical outcome. The close proximity of FLT3 to the centromere and the small number of SNP markers proximal to FLT3 on chromosome 13 means that in some cases, we cannot exclude the possibility of mechanisms other than mitotic recombination leading to uniparental disomy of chromosome 13. This could include nondisjunction followed by chromosome duplication. Mitotic recombination is clearly the case for WT1, RUNX1, and CEBPA mutation (Fig. 1) and suggests that mutation precedes mitotic recombination that acts to remove a normal copy of a gene and replace it with a mutated copy.

Before the introduction of SNP genotyping arrays, only a limited number of microsatellite markers could be used to detect the occurrence of mitotic recombination and the resultant uniparental disomy in tumors. In this manner, uniparental disomy has previously been shown on chromosome 9p in polycythemia vera (8). Recently, several groups have shown that a frequent mutational target in myeloproliferative disorders such as polycythemia vera is the JAK2 gene, located within 9p (9–12). Loss of heterozygosity at 9p is frequently observed in association with mutations to the JAK2 gene and has been shown to be due to mitotic recombination (9). Thus, mitotic recombination is playing a role in both myeloproliferative disorders and in AMLs, although clearly different mutational targets are involved.

In solid tumors, uniparental disomy has been observed in breast cancer (13), uveal melanoma (14), Wilm's tumors (15), and retinoblastoma (16). In addition, the background rate of mitotic recombination has been measured (17) in normal human and mouse cells to be ~10–4 to 10–5. Thus, given the widespread nature of mitotic recombination, it is therefore very probable that the acquisition of uniparental disomy has a similar role in other tumors. In this context, it is interesting that a recent SNP array study has shown that acquired uniparental disomy of chromosome 9q is common in basal cell carcinomas (18).

Our study indicates that mitotic recombination and the resultant uniparental disomy has a role in rendering a leukemic cell homozygous for a preexisting mutation. However, there may be other potentially important consequences. Uniparental disomy will, in principle, lead to alterations in expression levels of imprinted genes. In addition, it has recently been shown that there are allelic differences in gene expression levels (19) and therefore, if these are maintained after mitotic recombination, uniparental disomy could be associated with specific gene expression patterns.


   Acknowledgments
 
Grant support: Kay Kendall Leukaemia Fund and the Barts and Royal London Charitable Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Tracy Chaplin (Cancer Research UK) and Claire Taylor (Mutation Detection Facility).

Received 6/ 9/05. Accepted 7/18/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005;65:375–8.[Abstract/Free Full Text]
  2. Snaddon J, Smith ML, Neat M, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 2003;37:72–8.[CrossRef][Medline]
  3. Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer 1999;25:176–83.[CrossRef][Medline]
  4. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005;19:329–34.[CrossRef][Medline]
  5. Silva FP, Morolli B, Storlazzi CT, et al. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 2003;22:538–47.[CrossRef][Medline]
  6. Smith ML, Arch R, Smith LL, et al. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. Br J Haematol 2005;128:318–23.[CrossRef][Medline]
  7. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233–9.[Abstract/Free Full Text]
  8. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002;30:229–36.[CrossRef][Medline]
  9. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–90.[Abstract/Free Full Text]
  10. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–61.[Medline]
  11. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.[CrossRef][Medline]
  12. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–97.[CrossRef][Medline]
  13. Murthy SK, DiFrancesco LM, Ogilvie RT, Demetrick DJ. Loss of heterozygosity associated with uniparental disomy in breast carcinoma. Mod Pathol 2002;15:1241–50.[CrossRef][Medline]
  14. White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet 1998;102:40–5.[CrossRef][Medline]
  15. Shearer PD, Valentine MB, Grundy P, et al. Hemizygous deletions of chromosome band 16q24 in Wilms tumor: detection by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;115:100–5.[CrossRef][Medline]
  16. Hagstrom SA, Dryja TP. Mitotic recombination map of 13cen-13q14 derived from an investigation of loss of heterozygosity in retinoblastomas. Proc Natl Acad Sci U S A 1999;96:2952–7.[Abstract/Free Full Text]
  17. Tischfield JA. Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am J Hum Genet 1997;61:995–9.[CrossRef][Medline]
  18. Teh MT, Blaydon D, Chaplin T, et al. Genome-wide SNP microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. In press 2005.
  19. Lo HS, Wang Z, Hu Y, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003;13:1855–62.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
J. P. Maciejewski and G. J. Mufti
Whole genome scanning as a cytogenetic tool in hematologic malignancies
Blood, August 15, 2008; 112(4): 965 - 974.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Raghavan, L.-L. Smith, D. M. Lillington, T. Chaplin, I. Kakkas, G. Molloy, C. Chelala, J.-B. Cazier, J. D. Cavenagh, J. Fitzgibbon, et al.
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
Blood, August 1, 2008; 112(3): 814 - 821.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. Wang, C. Fidler, N. Nadig, A. Giagounidis, M. G. Della Porta, L. Malcovati, S. Killick, N. Gattermann, C. Aul, J. Boultwood, et al.
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
Haematologica, July 1, 2008; 93(7): 994 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. V. Balgobind, P. Van Vlierberghe, A. M. W. van den Ouweland, H. B. Beverloo, J. N. R. Terlouw-Kromosoeto, E. R. van Wering, D. Reinhardt, M. Horstmann, G. J. L. Kaspers, R. Pieters, et al.
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis
Blood, April 15, 2008; 111(8): 4322 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. Tyybakinoja, E. Elonen, H. Vauhkonen, J. Saarela, and S. Knuutila
Single nucleotide polymorphism microarray analysis of karyotypically normal acute myeloid leukemia reveals frequent copy number neutral loss of heterozygosity
Haematologica, April 1, 2008; 93(4): 631 - 632.
[Full Text] [PDF]

Home page
 BloodHome page
L. P. Gondek, R. Tiu, C. L. O'Keefe, M. A. Sekeres, K. S. Theil, and J. P. Maciejewski
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
Blood, February 1, 2008; 111(3): 1534 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Mohamedali, J. Gaken, N. A. Twine, W. Ingram, N. Westwood, N. C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, et al.
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Blood, November 1, 2007; 110(9): 3365 - 3373.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. F. Kormoczi, E.-M. Dauber, O. A. Haas, T. J. Legler, F. B. Clausen, G. Fritsch, M. Raderer, C. Buchta, A. L. Petzer, D. Schonitzer, et al.
Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting
Blood, September 15, 2007; 110(6): 2148 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. A. H. Neuwirth, M. Honma, and A. J. Grosovsky
Interchromosomal Crossover in Human Cells Is Associated with Long Gene Conversion Tracts
Mol. Cell. Biol., August 1, 2007; 27(15): 5261 - 5274.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. Agueli, R. Basirico, F. Fabbiano, V. Rizzo, L. Cascio, G. Cammarata, A. Marfia, M. La Rosa, S. Mirto, and A. Santoro
Loss of heterozygosity in acute leukemia: evidence of frequent submicroscopic deletions
Haematologica, May 1, 2007; 92(5): 678 - 681.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Akasaka, T. Balasas, L. J. Russell, K.-j. Sugimoto, A. Majid, R. Walewska, E. L. Karran, D. G. Brown, K. Cain, L. Harder, et al.
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Blood, April 15, 2007; 109(8): 3451 - 3461.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. P. Kratz, D. Steinemann, C. M. Niemeyer, B. Schlegelberger, E. Koscielniak, U. Kontny, and M. Zenker
Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome
Hum. Mol. Genet., February 15, 2007; 16(4): 374 - 379.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Blood, January 15, 2007; 109(2): 431 - 448.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. L. Andersen, C. Wiuf, M. Kruhoffer, M. Korsgaard, S. Laurberg, and T. F. Orntoft
Frequent occurrence of uniparental disomy in colorectal cancer
Carcinogenesis, January 1, 2007; 28(1): 38 - 48.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
H. Dohner
Implication of the Molecular Characterization of Acute Myeloid Leukemia
Hematology, January 1, 2007; 2007(1): 412 - 419.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Chapiro, L. Russell, I. Radford-Weiss, C. Bastard, M. Lessard, S. Struski, H. Cave, S. Fert-Ferrer, C. Barin, O. Maarek, et al.
Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia
Blood, November 15, 2006; 108(10): 3560 - 3563.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. P. Steensma
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
D. A. Peiffer, J. M. Le, F. J. Steemers, W. Chang, T. Jenniges, F. Garcia, K. Haden, J. Li, C. A. Shaw, J. Belmont, et al.
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping
Genome Res., September 1, 2006; 16(9): 1136 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Stephens, M. Weaver, K. A. Leppig, K. Maruyama, P. D. Emanuel, M. M. Le Beau, and K. M. Shannon
Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies
Blood, September 1, 2006; 108(5): 1684 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. A. Walker, P. E. Leone, M. W. Jenner, C. Li, D. Gonzalez, D. C. Johnson, F. M. Ross, F. E. Davies, and G. J. Morgan
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Blood, September 1, 2006; 108(5): 1733 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood, May 15, 2006; 107(10): 3847 - 3853.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitzgibbon, J.
Right arrow Articles by Young, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitzgibbon, J.
Right arrow Articles by Young, B. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online